From: Application of Max-SAT-based ATPG to optimal cancer therapy design
Drug Vector | Count | Coverage | Drug Vector | Count | Coverage |
---|---|---|---|---|---|
000001 | 3 | 23% | 000111 | 13 | 100% |
000010 | 2 | 15% | 001011 | 6 | 46% |
000100 | 2 | 15% | 001101 | 6 | 46% |
001000 | 1 | 8% | 001110 | 10 | 77% |
010000 | 2 | 15% | 010011 | 7 | 54% |
100000 | 3 | 23% | 010101 | 7 | 54% |
000011 | 5 | 38% | 010110 | 10 | 77% |
000101 | 3 | 23% | 011001 | 6 | 46% |
000110 | 10 | 77% | 011010 | 5 | 38% |
001001 | 4 | 31% | 011100 | 5 | 38% |
001010 | 3 | 23% | 100011 | 8 | 62% |
001100 | 3 | 23% | 100101 | 8 | 62% |
010001 | 5 | 38% | 100110 | 10 | 77% |
010010 | 4 | 31% | 101001 | 7 | 54% |
010100 | 4 | 31% | 101010 | 6 | 46% |
011000 | 3 | 23% | 101100 | 6 | 46% |
100001 | 6 | 46% | 110001 | 6 | 46% |
100010 | 5 | 38% | 110010 | 5 | 38% |
100100 | 5 | 38% | 110100 | 5 | 38% |
101000 | 4 | 31% | 111000 | 4 | 31% |
110000 | 3 | 23% | Â | Â | Â |